Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Huhn

Showing results (371-380 of 380) with videos related to

Pageof 38
Sort By:
You have reached the last page of results.This site can display upto 380 results.
Cancer Research|October 15, 1996
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumorsA S Lübbe, C Bergemann, H Riess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyRobert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.
Annals of Hematology|October 6, 1998
Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy appliedT Fischer, A Neubauer, J Mohm, et al.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Blut|September 1, 1981
Clinical and prognostic heterogeneity of non-Hodgkin lymphomas of high-grade malignancyU Schmalhorst, H Bartels, I Boll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1990
Interferons in the treatment of multiple myelomaD E Bergsagel, P von Wussow, R Alexanian, et al.
Blut|September 1, 1981
Principles and present status of a prospective multicenter study on the clinical relevance of the Kiel classificationG Brittinger, U Schmalhorst, H Bartels, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2019
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy VolunteersNandita Bose, Nadine R Ottoson, Xiaohong Qiu, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 38

Showing results (371-380 of 380) with videos related to

Sort By:
Pageof 38
You have reached the last page of results.This site can display upto 380 results.
Cancer Research|October 15, 1996
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumorsA S Lübbe, C Bergemann, H Riess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyRobert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.
Annals of Hematology|October 6, 1998
Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy appliedT Fischer, A Neubauer, J Mohm, et al.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Blut|September 1, 1981
Clinical and prognostic heterogeneity of non-Hodgkin lymphomas of high-grade malignancyU Schmalhorst, H Bartels, I Boll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1990
Interferons in the treatment of multiple myelomaD E Bergsagel, P von Wussow, R Alexanian, et al.
Blut|September 1, 1981
Principles and present status of a prospective multicenter study on the clinical relevance of the Kiel classificationG Brittinger, U Schmalhorst, H Bartels, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2019
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy VolunteersNandita Bose, Nadine R Ottoson, Xiaohong Qiu, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 38